Am J Transplant, Volume 17, Suppl 3 Archives - Page 17 of 181 - ATC Abstracts

2017 American Transplant Congress
Chronic Hepatitis E-Genotype 3 Infection in Transplant Recipients: A Single Kidney and Pancreas Transplant Centre Experience.
A. Kousios,¹ R. Charif,¹ E. Sanchez,² S. Khan,³ F. Regan,⁴ S. Ijaz,⁵ D. Muir,² B. Smith,³ R. Tedder,⁵ D. Taube,¹ J. Galliford.¹
¹Renal and Transplant Centre, Imperial College NHS Trust, London, United Kingdom; ²Department of Infection and Immunity, Imperial College NHS Trust, London, United Kingdom; ³Department of Hepatology, Imperial College NHS Trust, London, United Kingdom; ⁴Department of Hematology, Imperial College NHS Trust, London, United Kingdom; ⁵Blood Borne Virus Unit, Virus Reference Department, MS-Colindale, Public Health England, London, United Kingdom
Introduction:In the UK, Hepatitis E virus-genotype 3 (HEV3), is endemic and has now become the major cause of enterically transmitted viral hepatitis. Unlike HEV-genotype 1…
2017 American Transplant Congress
Risk Prediction Model for Delayed Graft Function in a Cohort of Brazilian Kidney Transplantation from Deceased Donors: What You See Is Not What You Get.
S. Costa,^1,2 T. Sandes-Freitas,^1,2 E. Daher,² R. Esmeraldo.¹
¹Hospital Geral de Fortaleza, Fortaleza, Brazil; ²Federal University of Ceara, Fortaleza, Brazil
Introduction: The estimated frequency of delayed graft function (DGF) in Brazil ranges from 50 to 70%, despite deceased donor and recipient characteristics similar to those…
2017 American Transplant Congress
Alemtuzumab Induction Is Associated with a Lower Incidence of BK Virus Nephropathy Compared with IL2RA Induction.
A. Gueret-Wardle, S. Hassan, G. Lucisano, C. Roufosse, M. Willicombe, D. Taube.
Renal Medicine, West London Renal and Transplant Centre, London, United Kingdom
Introduction:BK polyoma virus associated nephropathy [BKVAN] is a major cause of allograft dysfunction and graft loss occurring in up to 10% of kidney allograft recipients…
2017 American Transplant Congress
Cross-sectional and Serial Evolution of Quality of Life in Elderly Kidney Donors.
S. Ake,¹ D. Berglund,² S. Jackson,³ A. Matas,² C. Gross,² H. Ibrahim.²
¹Saint Catherine University, St. Paul; ²U of MN, Mpls; ³M Health, Mpls
Little is known regarding long-term health-related quality of life (HRQOL) in elderly (those donating when ≥65 yrs) living kidney donors (LKDs). Using the SF-36, we…
2017 American Transplant Congress
Influence of an Enhanced Recovery Protocol in Laparoscopic Living Donor Nephrectomy.
A. Rege, D. Vikraman, K. Ravindra, T. Brennan, H. Leraas, D. Sudan.
Surgery, Duke University Medical Center, Durham, NC
Background/Introduction: Enhanced recovery programs (ERPs) in colorectal surgery have decreased the duration of postoperative ileus and hospital stay while showing equivalent morbidity, mortality and readmission…
2017 American Transplant Congress
Modulating Ischemia-Reperfusion Injuries with Pharmacological Agents: A Bench-to-Bedside Approach.
M. Thomas, G. Tardif, A. Melanger, P. Berna.
Balmes Transplantation, Marseille, France
Ischemia–reperfusion (IR) is a complex pathophysiological process encompassing activation of inflammatory responses and cell death programs, the severity of which critically influences both the short…
2017 American Transplant Congress
ASP0113 Elicits an Immune Response in CMV-Seronegative Dialysis Patients: Comparison to Healthy Subjects.
P. Bonate,¹ C. Van Sant,² K. Cho,¹ E. Zook,¹ L. Smith,³ S. Boutsaboualoy, X. Wang,¹ R. Wu,¹ A. Koester,⁴ D. Rammelsberg,⁶ R. Goldwater,⁴ T. Marbury.⁵
¹Astellas Pharma Global Development, Northbrook; ²Astellas Research Institute of America, Skokie; ³Vical Inc, San Diego; ⁴PAREXEL International, Baltimore; ⁵Orlando Clinical Research Center, Orlando; ⁶Randstad Pharma, Deerfield, IL, United States (on assignment at Astellas Pharma Global Development, Northbrook, United States)
Introduction: ASP0113 is a first-in-class, DNA-based vaccine in development for the prevention of CMV infection in at-risk hematopoietic cell transplant.Methods: A Phase 1, single-blind, parallel-group,…
2017 American Transplant Congress
The Impact of Hepatitis C Treatment on GFR and Immunosuppression in Renal Transplant Recipients.
J. Husson, R. Adekunle, B. Ravichandran, P. Mathur, S. Jonchhe, K. Stafford.
University of Maryland Medical Center, Baltimore, MD
Background: Renal transplant recipients (RTRs) with HCV are at an increased risk of graft rejection, making treatment of HCV in this population of the utmost…
2017 American Transplant Congress
Usefulness of Valacyclovir Prophylaxis for Preventing Cytomegalovirus Infection After Anti-Thymocyte Globulin Treatment as Antirejection Therapy.
E. Ko,^1,2 J. Yu,^1,2 B. Choi,^1,2 C. Park,^1,2 Y. Kim,^1,2 C. Yang,^1,2 B. Chung.^1,2
¹Transplant Research Center, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea; ²Division of Nephrology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
Anti-thymocyte globulin (ATG) treatment for acute T-cell mediated rejection (TCMR) can increase the risk of CMV infection. We purposed to evaluate the effect of valacyclovir…
2017 American Transplant Congress
BKV Clearance Time Correlates with T-Cell Receptor Repertoire Shape and Exhaustion State of BKV-Specific T-Cells in Renal Transplant Patients with Severe BKV Infection.
U. Stervbo,^1,2 M. Nienen,¹ B. Weist,² P. Wehler,² T. Westhoff,¹ H.-D. Volk,² P. Reinke,² N. Babel.^1,2
¹Center for Translational Medicine, Medical Clinic I, Marienhospital Herne, University Hospital of the Ruhr-University Bochum, Bochum, Germany; ²Berlin-Brandenburg Center for Regenerative Therapies, Charité – University Medicine, Berlin, Germany
Reactivation of the BK polyomavirus is known to lead to severe complications in kidney transplant patients. The current treatment strategy relies on decreasing the immunosuppression…